Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma.
Kim YH, Duvic M, Obitz E, Gniadecki R, Iversen L, Osterborg A, Whittaker S, Illidge TM, Schwarz T, Kaufmann R, Cooper K, Knudsen KM, Lisby S, Baadsgaard O, Knox SJ.
Kim YH, et al. Among authors: knox sj.
Blood. 2007 Jun 1;109(11):4655-62. doi: 10.1182/blood-2006-12-062877. Epub 2007 Feb 20.
Blood. 2007.
PMID: 17311990
Free article.
Clinical Trial.